Pharmacological Options in Cushing's Syndrome
- corresponding Author:
- Edgar Perez Duran Geardo
Highly Specialized Regional Hospital Bajio
Leon Guanajuato, Mexico
Tel: 52-477-2672000 ext 1414
E-mail: [email protected]
Received Date: November 28, 2012; Accepted Date: December 28, 2012; Published Date: January 03, 2013
Citation: Edgar Gerardo DP, Oscar Tarcicio ML, Antonio SP, Ismael Javier CL, German CT, et al. (2013) Pharmacological Options in Cushingâ€™s Syndrome. Endocrinol Metab Synd 2:110. doi: 10.4172/2161-1017.1000110
Copyright: © 2013 Edgar Gerardo DP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The endogenous Cushing’s syndrome is a pathology which represents a diagnostic and therapeutic challenge for the specialist. Even though surgery is the first-line treatment, it is common to resort to pharmacological therapy in the preoperative setting because of the clinical instability or because the purpose is improving the medical condition of the patient before the surgery. Furthermore, because of the low successful rates with the surgical approach, the adjuvant pharmacological treatment ranks the first place because its purpose is to improve the possibilities of disease remission. This review deals with the current pharmacological therapies for the management of endogenous Cushing’s syndrome.